Shots: The approval is based on P-III ‘1053’ trial conducted across 34 sites in 14 countries assessing Lumoxiti (moxetumomab pasudotox-tdfk) in patients with r/r HCL, testing its safety, efficacy, immunogenicity […]readmore
Tags : R/R 2L+